Article
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Cancer chemotherapy and pharmacology - 1 May 2020
Huijberts Sanne C F A, van Geel Robin M J M, van Brummelen Emilie M J, Opdam Frans L, Marchetti Serena, Steeghs Neeltje, Pulleman Saskia, Thijssen Bas, Rosing Hilde, Monkhorst Kim, Huitema Alwin D R, Beijnen Jos H, Bernards René, Schellens Jan H M
Abstract excerpt
PURPOSE: KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo. In this phase I study, patients with advanced KRASm and PIK3CA wild-type colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer, were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.